文献速递肝病消化道肿瘤与早癌

肝细胞癌临床显著门静脉高压的无创预测:肿瘤校正模型

Noninvasive Prediction of Clinically Significant Portal Hypertension in Hepatocellular Carcinoma: A Tumor-Adjusted Model.
PubMed 文献 · Am J Gastroenterol · 2026-09-17

本研究回顾性分析452例代偿期肝硬化合并肝细胞癌患者,评估肝脏硬度测量(LSM)与肝静脉压力梯度(HVPG)的相关性,并开发肿瘤校正模型(Baveno-HCC)预测临床显著门静脉高压(CSPH)。结果显示LSM与HVPG中度相关(r=0.593),Baveno VII标准排除CSPH敏感性高但确认性能有限,Baveno-HCC模型提高了确认性能,尤其在肿瘤负荷>5 cm患者中阳性预测值显著提升。

要点

  • LSM与HVPG中度相关,但大肿瘤(>5 cm)患者准确性降低。
  • Baveno VII标准排除CSPH敏感性>90%,但确认性能有限。
  • Baveno-HCC模型提高确认性能,肿瘤>5 cm者阳性预测值提升。

核心结论

  • 肿瘤负荷和位置影响基于LSM的CSPH评估,Baveno-HCC模型可改善CSPH预测并支持更准确的风险分层。

研究设计与样本

  • 多中心回顾性研究,纳入452例代偿期肝硬化合并肝细胞癌患者,LSM和HVPG在三个月内完成。
  • 推导队列316例,验证队列136例。

主要发现

  • LSM与HVPG中度相关(r=0.593,p<0.001),大右叶肿瘤(>5 cm)患者准确性降低。
  • Baveno VII标准排除CSPH敏感性和阴性预测值均>90%,但确认性能有限,尤其在大肿瘤患者中。
  • Baveno-HCC模型(包含LSM、血小板计数、脾脏大小和肿瘤负荷)提高确认性能,阳性预测值在推导队列从46.2%升至84.6%,验证队列从56.3%升至100.0%。

关键数值与推荐

  • Baveno VII标准:排除CSPH的敏感性和阴性预测值>90%。
  • Baveno-HCC模型阳性预测值:肿瘤负荷>5 cm患者推导队列46.2%→84.6%,验证队列56.3%→100.0%。

临床怎么用

  • 对于肝细胞癌合并代偿期肝硬化患者,可采用Baveno-HCC模型无创预测CSPH,辅助风险分层和临床决策。

局限性

  • 回顾性研究设计可能引入选择偏倚。
  • 样本量有限,需进一步外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Noninvasive assessment of clinically significant portal hypertension (CSPH) using liver stiffness measurement (LSM) and platelet count (per Baveno VII criteria) may be influenced by tumor-related factors in patients with hepatocellular carcinoma (HCC). We evaluated the relationship between LSM and hepatic venous pressure gradient (HVPG) and developed a tumor-adjusted model for CSPH prediction in HCC. METHODS: In this multicenter study, 452 patients with compensated cirrhosis and HCC who underwent LSM and HVPG within three months were retrospectively analyzed. The correlation between LSM and HVPG was assessed, including stratification by tumor characteristics. A tumor-adjusted predictive model (Baveno-HCC) was developed in a derivation cohort (n=316) and validated in a separate cohort (n=136). RESULTS: LSM correlated moderately with HVPG (r=0.593, p<0.001), with reduced accuracy in patients with large (>5 cm) right-lobe tumors. Baveno VII criteria maintained high sensitivity and negative predictive value (>90%) for ruling out CSPH but showed limited rule-in performance, particularly in patients with larger tumors. The Baveno-HCC model, incorporating LSM, platelet count, spleen size, and tumor burden, improved rule-in performance with higher positive predictive value (PPV) while preserving rule-out accuracy. Improvements were most pronounced in patients with tumor burden >5 cm, with PPV increasing from 46.2% to 84.6% in the derivation cohort and from 56.3% to 100.0% in the validation cohort. DISCUSSION: Tumor burden and location affect LSM-based CSPH assessment. The proposed Baveno-HCC model improves CSPH prediction and supports more accurate risk stratification and clinical decision-making in patients with HCC.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Demirtas CO, Mezzacappa C, Sartoris R, et al. Noninvasive Prediction of Clinically Significant Portal Hypertension in Hepatocellular Carcinoma: A Tumor-Adjusted Model. Am J Gastroenterol. 2026. PMID: 42750637. doi:10.14309/ajg.0000000000004204

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。